C12N 2760/16023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2760/16023 (Virus like particles [vlp]) appears on 35 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 35
- Published applications
- 47
- Assignees
- 20
- Inventors
- 62
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 0 | 2 |
| 2013 | 2 | 2 |
| 2014 | 0 | 1 |
| 2015 | 5 | 4 |
| 2016 | 3 | 3 |
| 2017 | 2 | 3 |
| 2018 | 3 | 2 |
| 2019 | 1 | 3 |
| 2020 | 4 | 4 |
| 2021 | 1 | 7 |
| 2022 | 3 | 3 |
| 2023 | 1 | 2 |
| 2024 | 4 | 1 |
| 2025 | 3 | 1 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of generating broadly protective vaccine compositions comprising neuraminidase13 Jan 2026US 12,521,430 B2Sanofi Pasteur Limited
- Influenza virus hemagglutinin mutants30 Sep 2025US 12,428,661 B2Aramis Biotechnologies Inc.
- Influenza B virus replication for vaccine development22 Jul 2025US 12,364,748 B2Wisconsin Alumni Research Foundation (WARF)
- Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions14 Jan 2025US 12,194,087 B2George Mason University
- Influenza virus hemagglutinin mutants12 Nov 2024US 12,139,511 B2Aramis Biotechnologies Inc.
- Switchable mrna expression platform6 Aug 2026US 2026/0224679 A1
- Influenza b virus replication for vaccine development12 Feb 2026US 2026/0041756 A1Wisconsin Alumni Research Foundation (WARF)
- Influenza virus hemagglutinin mutants17 Apr 2025US 2025/0122549 A1Aramis Biotechnologies Inc.
- Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses28 Nov 2024US 2024/0390473 A1Verimmune Inc.
- Compositions and devices for vaccine release and uses thereof31 Aug 2023US 2023/0270842 A1Vaxess Technologies, Inc.
Most cited
By later US patents
- Functional influenza virus-like particles (VLPs)35US 7,763,450 B2Novavax, Inc. · 2010
- Functional influenza virus like particles (VLPs)35US 8,080,255 B2Novavax, Inc. · 2011
- Functional influenza virus like particles (VLPs)20US 8,506,967 B2Novavax, Inc. · 2013
- Functional influenza virus-like particles (VLPs)17US 8,592,197 B2Novavax, Inc. · 2013
- Influenza B virus replication for vaccine development16US 11,197,925 B2Wisconsin Alumni Research Foundation (WARF) · 2021